

Contents of *The American Journal of Psychiatry*

November 1996

Volume 153

Editorial	
A changing psychiatry for the future. <i>Herbert Pardes</i>	1383
Images in Neuroscience	
Molecular biology, I: a mouse knockout. <i>Essay by Marc G. Caron</i>	1387
Special Articles	
Redefining the role of psychiatry in medicine. <i>Jeffrey A. Lieberman and A. John Rush</i>	1388
Psychiatry at a crossroad: our role in primary care. <i>James H. Shore</i>	1398
Regular Articles	
Does major depression result in lasting personality change? <i>M. Tracie Shea, Andrew C. Leon, Timothy I. Mueller, David A. Solomon, Meredith G. Warshaw and Martin B. Keller</i>	1404
Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. <i>Lewis L. Judd, Martin P. Paulus, Kenneth B. Wells and Mark H. Rapaport</i>	1411
High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. <i>Charles F. Reynolds III, Ellen Frank, James M. Perel, Sati Mazumdar, Mary Amanda Dew, Amy Begley, Patricia R. Houck, Martica Hall, Benoit Mulsant, M. Katherine Shear, Mark D. Miller, Cleon Cornes and David J. Kupfer</i>	1418
Predictors of response and nonresponse to light treatment for winter depression. <i>Michael Terman, Leora Amira, Juan Su Terman and Donald C. Ross</i>	1423
Changes in depressive symptoms as AIDS develops. <i>Constantine G. Lyketsos, Donald R. Hoover, Marcella Guccione, Mary Amanda Dew, Jerry E. Wesch, Eric G. Bing and Glenn J. Treisman, for the Multicenter AIDS Cohort Study</i>	1430
Longitudinal assessment of symptoms of depression, agitation and psychosis in 181 patients with Alzheimer's disease. <i>Morgan L. Levy, Jeffrey L. Cummings, Lynn A. Fairbanks, Daniele Bravi, Menotti Calvani and Angelico Carta</i>	1438
Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. <i>Peter Roy-Byrne, Dane K. Wingerson, Allen Radant, David J. Greenblatt and Deborah S. Cowley</i>	1444
Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? <i>Lorin M. Koran, John W. Cain, Roberto A. Dominguez, A. John Rush and Sue Thiemann</i>	1450
<i>d</i> -fenfluramine treatment of binge eating disorder. <i>Albert Stunkard, Robert Berkowitz, Cigdem Tanrikut, Elizabeth Reiss and Lisa Young</i>	1455
<i>d</i> -fenfluramine-induced prolactin responses in mania: evidence for serotonergic subsensitivity. <i>Jogin H. Thakore, Veronica O'Keane and Timothy G. Dinan</i>	1460
Insanity defense pleas in Baltimore City: an analysis of outcome. <i>Jeffrey S. Janofsky, Mitchell H. Dunn, Erik J. Roskes, Jonathan K. Briskin and Maj-Stina Lunstrum Rudolph</i>	1464
Attitudes of Oregon psychiatrists toward physician-assisted suicide. <i>Linda Ganzini, Darien S. Fenn, Melinda A. Lee, Ronald T. Heintz and Joseph D. Bloom</i>	1469
Clinical Case Conference	
Developmental arrest and maternal loss in an adolescent girl with lupus erythematosus and terminal renal failure. <i>Beverly Stoute, Theodore Shapiro and Milton Viederman</i>	1476
Images in Psychiatry	
John Bowlby, 1907–1990. <i>Essay by George E. Vaillant</i>	1483
Brief Reports	
Complicated grief as a disorder distinct from bereavement-related depression and anxiety: a replication study. <i>Holly G. Prigerson, Andrew J. Bierhals, Stanislav V. Kasl, Charles F. Reynolds III, M. Katherine Shear, Jason T. Newsom and Selby Jacobs</i>	1484
Unreliability of current screening tests for syphilis in chronic psychiatric patients. <i>Roy R. Reeves, Harold B. Pinkofsky and Kathryn K. Kennedy</i>	1487
The burden of conditions not attributable to mental disorders. <i>C. M. Siddique, Tim D. Aubry and David Mulhall</i>	1489
Cognitive functioning and posttraumatic stress disorder. <i>Drue H. Barrett, Michelle L. Green, Robin Morris, Wayne H. Giles and Janet B. Croft</i>	1492

The American Journal of Psychiatry is now on the Web! The *Journal's* home page features this month's table of contents, abstracts for every article, and full text of editorials, images in neuroscience, and images in psychiatry. Also featured is next month's table of contents, back issue abstracts, subscription information, and information for authors. You can access the *Journal's* home page at <http://www.appi.org/ajp>.

Books from Gaskell



Available from good bookshops and from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. 0171-235 2351, extension 146)

Mental Disorders in China

English Version Editors:

John E. Cooper & Norman Sartorius

This is the first available account in English of the results of the 1982 Chinese Epidemiological Survey of Mental Disorder. It is the only nationwide Chinese study to involve modern methods of case assessment and is uniquely large and interesting, involving 51 982 persons. The use of the Present State Examination in the survey allows the symptomatic basis of diagnoses, such as neurasthenia, to be examined. The results indicate that the prevalence of schizophrenia is similar to that found recently in other countries, but that the prevalence of other mental disorders may be lower.

• £15.00 • 128pp. • 1996 • ISBN 0 902241 93 1

Mental Health Care in China

State Policies, Professional Services and Family Responsibilities

by Veronica Pearson

This book traces the development of psychiatric services in China. Historical, policy and legal frameworks are constructed to provide a context in which psychiatric services may be better understood. The experience of both staff and patients in one particular hospital is examined in detail. The book raises questions about the similarities in the experience of psychiatric illness across significantly different cultures.

• £12.50 • 218pp. • 1995 • ISBN 0 902241 74 5

Epilim Oral Prescribing Information

Presentation Epilim 200 Enteric Coated and Epilim 500 Enteric Coated: Enteric coated tablets containing 200mg, and 500mg Sodium Valproate Ph.Eur. respectively. Epilim Crushable Tablets containing 100mg Sodium Valproate Ph.Eur. Epilim Syrup and Epilim Liquid (sugar free) both containing 200mg Sodium Valproate Ph.Eur. per 5ml. Epilim Chrono 200, Epilim Chrono 300, and Epilim Chrono 500: Controlled release tablets containing a mixture of Sodium Valproate Ph.Eur. and Valproic Acid Fr.P. equivalent to 200mg, 300mg, and 500mg Sodium Valproate respectively. **Indications** Oral formulations of Epilim are indicated for all types of epilepsy. In women of child bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and administration** *Adults*; the dose should be titrated at three day intervals until seizure control is achieved. Initially 600mg a day increasing in steps of 200mg to a maximum dose of 2500mg per day. *Children over 20kg*; initially 400mg a day increasing in steps to a maximum dose of 35mg/kg/day. *Children under 20kg*; initially 20mg/kg/day - the dose may be increased in severe cases provided that plasma levels are monitored; above 40mg/kg/day chemistry and haematology should be monitored. Epilim Chrono may be given once or twice daily. All other formulations should be given twice daily. **Combination therapy**; levels of Epilim and co-administered anticonvulsants may be affected and optimum dosage is determined by seizure control. **Contraindications, Warnings, etc.** **Contraindications** Active liver disease, family history of severe liver disease, hypersensitivity to valproate. **Side effects** Impaired hepatic function, particularly in children, occasionally leading to hepatic failure - treatment should be withdrawn in patients who suddenly develop symptoms compatible with hepatic disease such as nausea, anorexia, jaundice or malaise. Hyperammonaemia with or without hepatic dysfunction. Blood dyscrasia - impaired platelet function, thrombocytopenia, occasional leucopenia and red cell hypoplasia. Occasionally increased appetite, weight gain, transient hair loss, behavioural disturbances, alterations to the menstrual cycle and pancreatitis. Symptoms of intoxication include ataxia, tremor, and stupor. **Drug interactions** Epilim has significant interactions with phenytoin, lamotrigine and other anticonvulsants. Epilim may potentiate the effects of neuroleptics, MAOIs and other antidepressants, anticoagulants and salicylates. Cimetidine may inhibit the metabolism of Epilim. Epilim has no effect on the efficacy of oral contraceptives. **Pregnancy** An increased incidence of congenital abnormalities has been demonstrated in offspring born to mothers with epilepsy both untreated and treated, including those treated with sodium valproate. Neural tube defects have been reported in about 1% of offspring of women who have received valproate during the first trimester of pregnancy. Pregnancies should be screened for neural tube defects by estimation of alpha-fetoprotein and ultrasound. Folate supplementation has been shown to reduce the incidence of neural tube defects in the offspring of high risk women. **Legal category** P.O.M. **Further information** Epilim is hygroscopic - tablets should not be removed from their foil until they are used. Epilim Chrono is recommended in cases where plasma valproate levels are being measured on account of its pharmacokinetics. The effective therapeutic range for valproate is 40-100mg/l (278-694 micromol/l). **Product Licence Numbers** Epilim 200 Enteric Coated 11723/0018, Epilim 500 Enteric Coated 11723/0020, Epilim 100mg Crushable Tablets 11723/0017, Epilim Syrup 11723/0025, Epilim Liquid 11723/0024, Epilim Chrono 200 11723/0078, Epilim Chrono 300 11723/0021, Epilim Chrono 500 11723/0079. **NHS Cost** Epilim 200 Enteric Coated 100 tablets £6.42, Epilim 500 Enteric Coated 100 tablets £16.04, Epilim 100mg Crushable Tablets 100 tablets £3.89, Epilim Syrup 300ml £5.89, Epilim Liquid 300ml £5.89, Epilim Chrono 200 100 tablets £7.70, Epilim Chrono 300 100 tablets £11.55, Epilim Chrono 500 100 tablets £19.25. **Address**: Sanofi Winthrop Ltd., One Onslow Street, Guildford, Surrey GU1 4YS. **Telephone**: (01483) 505515 **Fax**: (01483) 35432. Epilim, Epilim Chrono and the Chrono device are registered trade marks. **Date of preparation**: May 1996.

References:

1. Chadwick D., *J. Neurol. Neurosurg. Psychiatry* 1994; **57**: 264-277.
2. Gilham R.A., *Epilepsy Res.*, 1990; **7**: 219-225.



Give someone with epilepsy a future to look forward to

People with epilepsy have the same aspirations as anybody else. What they need is a treatment which allows them to fulfil their potential.

Whatever the type of epilepsy, Epilim Chrono can help. Effective both in generalized and partial seizures,¹ it is well tolerated (particularly with regard to cognitive function)², and offers patients the convenience of once-daily dosing.

It helps people with epilepsy get on with their lives today, and look forward to tomorrow.



Epilim[®] CHRONO[®]
Sodium Valproate Ph. Eur.
Valproic Acid Fr.P Controlled Release

**Once-daily management
for all forms of epilepsy**

REASON TO BE CHEERFUL



LUSTRAL™ 50mg
sertraline



Established in treating depression



Abbreviated Prescribing Information:
LUSTRAL™ (sertraline) Presentation: Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness and accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes including accompanying symptoms of anxiety. **Dosage:** LUSTRAL should be given as a single daily dose. The initial dose is 50mg and the usual therapeutic dose is 50mg daily. Dosage can be further increased, if appropriate, to 150mg or a maximum of 200mg daily. Patients should be maintained on the lowest effective dose and doses of 150mg or more should not be used for periods exceeding 8 weeks. **Use in children:** Not recommended. **Use in the elderly:** Usual adult dose. **Contra-indications:**

Hypersensitivity to LUSTRAL. Hepatic insufficiency. **Use during pregnancy:** LUSTRAL should be used only if clearly needed. **Lactation:** Not recommended. **Precautions, warnings:** Renal insufficiency, unstable epilepsy, ECT, driving. LUSTRAL should be discontinued in a patient who develops seizures. LUSTRAL should not be administered to patients concurrently being treated with tranquilizers who drive or operate machinery. Do not use with, or within two weeks of ending treatment with, MAOIs. At least 14 days should elapse before starting any MAOI following discontinuation of LUSTRAL. Patients should be closely supervised for the possibility of suicide attempt or activation of mania/hypomania. **Drug interactions:** Administer with caution in combination with other centrally active medication. Serotonergic drugs including tryptophan, sumatriptan and fenfluramine should not be used with LUSTRAL. It is recommended that plasma lithium levels be monitored following initiation of LUSTRAL. Although LUSTRAL has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for LUSTRAL to interact with other highly protein bound drugs should be borne

in mind. The potential of LUSTRAL to interact with e.g. warfarin, diazepam, tolbutamide and cimetidine has not been fully assessed. With warfarin prothrombin time should be monitored when LUSTRAL is initiated or stopped. **Side-effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating, dyspepsia, dizziness, insomnia and somnolence. Asymptomatic elevations in serum transaminases have been reported infrequently (approx. 0.8%) in association with LUSTRAL. These usually occurred within the first 9 weeks treatment and resolved on cessation of therapy. Malaise and rash have been reported. Seizures (see precautions, warnings). There have been isolated reports of movement disorders and rare cases of hyponatraemia. **Legal category:** POM. **Basic NHS cost:** 50mg tablet (PL 570308) Calendar pack of 28, £26.51; 100mg tablet (PL 570309) Calendar pack of 28, £39.77. Further information on request.

Invicta™ Pharmaceuticals or
Richborough™ Pharmaceuticals
Divisions of Pfizer Limited, Sandwich, Kent.

